Merck especially likes the life science sector, which includes research labs and biotech and pharma companies, because of the highly predictable and stable demand from customers, Garijo said.
The company is also interested in making deals — either bolt-on or bigger takeovers — to bolster its portfolio of medicines or to strengthen its semiconductor solutions business. Merck’s last multibillion deal was the 2019 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.